Welcome to our dedicated page for Retractable Tech SEC filings (Ticker: RVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Retractable Technologies, Inc. filings document the regulatory record for a Texas medical device manufacturer whose common stock trades on NYSE American under RVP. Recent Form 8-K reports cover material events such as operating-results releases, workforce reductions, product designation announcements, and dividends on Series II and Series III Class B Convertible Preferred Stock.
The company’s proxy materials disclose annual meeting matters, director elections, board structure, shareholder voting procedures, and executive-governance information. Together, the filings describe Retractable’s public-company capital structure, recurring event disclosures, governance processes, and formal exhibits tied to its safety medical products business.
Retractable Technologies (RVP) filed its Q3 2025 10‑Q, reporting sales of $10,085,723 and net income of $371,047 (EPS $0.01). Gross profit was $1.69M with a loss from operations of $3.65M, offset by Other income – TIA of $1.52M and an unrealized gain on investments of $2.38M.
For the first nine months, sales were $28,826,629 with a net loss of $(10,217,140). Cash was $3.44M and investments at fair value were $30.50M; other long‑term liabilities related to the TIA were $59.40M. Three significant customers represented 57.3% of Q3 net sales.
The company highlighted tariff headwinds on China‑sourced syringes and needles, with prevailing rates at 130%. Tariff expense was $172K in Q3 and $2.3M year‑to‑date. Management is shifting more production to its U.S. facility, which raises payroll by about $825K annually but is expected to reduce tariff exposure. Inventory write‑downs were about $1.2M year‑to‑date. Shares outstanding were 29,937,159 as of November 3, 2025.
Retractable Technologies (RVP) filed its Q3 2025 10‑Q, reporting sales of $10,085,723 and net income of $371,047 (EPS $0.01). Gross profit was $1.69M with a loss from operations of $3.65M, offset by Other income – TIA of $1.52M and an unrealized gain on investments of $2.38M.
For the first nine months, sales were $28,826,629 with a net loss of $(10,217,140). Cash was $3.44M and investments at fair value were $30.50M; other long‑term liabilities related to the TIA were $59.40M. Three significant customers represented 57.3% of Q3 net sales.
The company highlighted tariff headwinds on China‑sourced syringes and needles, with prevailing rates at 130%. Tariff expense was $172K in Q3 and $2.3M year‑to‑date. Management is shifting more production to its U.S. facility, which raises payroll by about $825K annually but is expected to reduce tariff exposure. Inventory write‑downs were about $1.2M year‑to‑date. Shares outstanding were 29,937,159 as of November 3, 2025.
Retractable Technologies (RVP) reported an insider transaction by its President and CEO, a Director and 10% Owner. On 11/11/2025, the insider purchased 100 shares of common stock at a weighted average price of $0.8111 (Code P).
Following the transaction, beneficial ownership was 15,825,491 shares direct and 831,600 shares indirect. The filing notes that the insider has investment power over 500,000 shares as Trustee for a family member and voting control over the remainder pursuant to a voting agreement. A Rule 10b5-1 plan was adopted on August 22, 2024.
Retractable Technologies (RVP) reported an insider purchase by its President & CEO, Director, and 10% Owner, Mr. Shaw. On 11/05/2025, he acquired 7,500 shares of common stock at a weighted average price of $0.826 (transaction code P).
Following this trade, Mr. Shaw beneficially owns 15,825,391 shares directly and 831,600 shares indirectly. The indirect holdings include 500,000 shares over which he has investment power as Trustee for a family member, with voting control over the remainder pursuant to a voting agreement.
The filing notes a Rule 10b5-1 trading plan, with a date of adoption of August 22, 2024.
Retractable Technologies (RVP) disclosed an insider share purchase by President & CEO, Director, and 10% Owner Thomas J. Shaw. On 10/30/2025, he reported buying 15,000 shares of common stock (transaction code P) at a $0.861 weighted average price.
Following the transaction, Mr. Shaw beneficially owns 15,817,891 shares directly and 831,600 shares indirectly, noted as “Voting or Investment Control.” The filing explains he has investment power over 500,000 shares as trustee for a family member and voting control over the remainder under a voting agreement. The transaction was made under a Rule 10b5-1 plan adopted on August 22, 2024.
Retractable Technologies (RVP) reported an insider transaction by President and CEO Thomas J. Shaw, who is also a director and 10% owner. On 10/28/2025, he purchased 35,000 shares of common stock at a weighted average price of $0.9151 (transaction code P).
Following this trade, Mr. Shaw beneficially owns 15,802,891 shares directly and 831,600 shares indirectly with “Voting or Investment Control.” The filing notes he has investment power over 500,000 shares as Trustee for a family member and voting control over the remainder pursuant to a voting agreement. A Rule 10b5‑1 plan was adopted on August 22, 2024.
Retractable Technologies (RVP) President and CEO (also Director and 10% Owner) reported a purchase of 34,506 shares of common stock on 10/27/2025 at a weighted average price of $0.9425 (Transaction Code: P).
Following the transaction, beneficial ownership stands at 15,767,891 shares held directly and 831,600 shares held indirectly. The filing notes a Rule 10b5-1 plan adopted on August 22, 2024. Indirect holdings include 500,000 shares over which the insider has investment power as Trustee for a family member, and voting control over the remainder pursuant to a voting agreement.
Retractable Technologies (RVP) reported an insider purchase by Mr. Shaw, its President and CEO, Director, and 10% Owner. On 10/23/2025, he bought 356 shares of common stock at a weighted average price of $0.951, made pursuant to a Rule 10b5-1(c) trading plan adopted on August 22, 2024.
Following the transaction, Mr. Shaw beneficially owns 15,733,385 shares directly and 831,600 shares indirectly. The indirect holdings include 500,000 shares over which he has investment power as trustee for a family member, and he has voting control over the remainder pursuant to a voting agreement.
Retractable Technologies (RVP) reported an insider purchase by its President, CEO, Director, and 10% owner, Mr. Shaw. On 10/22/2025, he acquired 10,000 shares of common stock at a weighted average price of $0.96 (Form 4, code P).
Following the transaction, he beneficially owns 15,733,029 shares directly and 831,600 shares indirectly. As noted, he has investment power over 500,000 shares as trustee for a family member and voting control over the remainder pursuant to a voting agreement. A Rule 10b5-1 plan was noted with an adoption date of August 22, 2024.
Retractable Technologies (RVP): Mr. Shaw (Director, President and CEO, and 10% Owner) reported a purchase of 14,204 shares of common stock on 10/14/2025 at a weighted average price of $0.9256 (transaction code P).
Following the transaction, he beneficially owns 15,723,029 shares directly and 831,600 shares indirectly. The indirect holdings include 500,000 shares over which he has investment power as Trustee for a family member and the remainder subject to a voting agreement. A Rule 10b5-1 plan was adopted on August 22, 2024.
Retractable Technologies, Inc. reporting person Thomas J. Shaw (President, CEO, Director and >10% owner) acquired 30,000 shares of common stock on 10/08/2025 at a weighted average price of $0.9233. After the purchase Mr. Shaw beneficially owns 15,708,825 shares directly and has an indirect beneficial interest in 831,600 shares as Trustee for a family member; voting control over the remainder is held via a voting agreement. The transaction was executed under a Rule 10b5-1 trading plan adopted on Aug 22, 2024. The Form 4 was signed by an attorney-in-fact on 10/09/2025.